SPONSORED CONTENT
While specialty drugs were used by less than 2% of the population in 2020, “they accounted for almost 51% of spending under the pharmacy benefit.”[1] Within your 340B program, these numbers can be even higher. On average, we see about six percent of volume resulting in close to fifty percent of savings
…
Drug manufacturer Lilly and the federal government disagree over whether a federal district judge’s recent decision in Lilly’s 340B contract pharmacy case is ripe for review.
Last month, the U.S. Seventh Circuit Court of Appeals questioned whether U.S. Senior
…
340B hospitals’ challenge to Medicare Part B drug reimbursement cuts was not the only case on the U.S. Supreme Court docket this week that could have a significant impact on the program.
On Monday, the justices heard the case of
…
UPDATED Wednesday Dec. 1, 2021, 1:15 p.m. EST—Includes comments from Amgen, HRSA, and hospital group 340B Health.
Biopharmaceutical manufacturer Amgen this morning became the 10th pharmaceutical company to announce conditions on 340B pricing when contract pharmacies dispense medicines to
…
Several U.S. Supreme Court justices asked during a hearing today whether the Centers for Medicare & Medicaid Services (CMS) had statutory authority to single out 340B hospitals for a nearly 30% cut in Medicare Part B drug reimbursement beginning in
…
The U.S. Supreme Court is hearing arguments this morning in a lawsuit challenging the nearly 30% cut since 2018 in what Medicare Part B pays hospitals for 340B-purchased physician administered drugs.
Arguments in American Hospital Association v. Becerra are due
…
Drug manufacturer Clovis Oncology has decided for now not to implement drug discount management company Kalderos’ 340B Pay service to let drug companies pay 340B ceiling prices as back-end rebates instead of as front-end discounts, Kalderos said late yesterday.
“We
…
U.S. Rep. Peter Welch (D-Vt.), who has backed 340B covered entities in several policy battles, is running to succeed his fellow Democrat Patrick Leahy in the U.S. Senate.
Senate President Pro Tempore Leahy, 81, announced on Nov. 15 that he
…
Belgian-based pharmaceutical manufacturer UCB this morning became the ninth drug company to impose limits on 340B pricing involving contract pharmacies.
Hospitals reported getting letters and an FAQ from UCB today by email announcing that, effective Dec. 13 and with
…*Sign up for news summaries and alerts from 340B Report
